SHH and neoplasm: Treatment of medulloblastomas in mice with an anti-mitotic drug or sonic hedgehog (SHH) pathway inhibitor resulted in residual tumors that were enriched in SOX2+ cells, indicating that these cells were likely to contribute toward tumor relapse [32].